Literature DB >> 8840004

Thromboembolic disease developing during oral contraceptive therapy in young females with antiphospholipid antibodies.

A Girolami1, E Zanon, S Zanardi, M A Saracino, P Simioni.   

Abstract

The role of oral contraceptives as a triggering factor for thrombosis in patients with lupus anticoagulant (LA) and/or anticardiolipin antibodies (ACA) has not yet been established. We describe the cases of three women aged 19, 29 and 48 years who developed venous thrombosis after 16 +/- 3.4 (mean +/- SD) cycles of oral contraceptives. They were all asymptomatic before taking the pill. Two patients subsequently developed venous and/or arterial recurrence of thrombosis. Laboratory studies performed after the diagnosis of thrombosis, showed the presence of LA and elevated levels of ACA (IgG and IgM) in all three patients. None of these patients had autoimmune diseases and therefore appeared to have a primary antiphospholipid antibody syndrome. The three patients belonged to a group of 45 young females who experienced their first thrombotic event while taking the pill. This group had a similar prevalence (8%) for antithrombin deficiency and antiphospholipid antibodies. We surmise that some of the women who developed venous thrombosis while taking the pill might have an undetected primary antiphospholipid syndrome.

Entities:  

Keywords:  Antibodies; Biology; Case Studies; Contraception; Contraceptive Methods; Developed Countries; Diseases; Embolism; Europe; Family Planning; Immunity; Immunologic Factors; Italy; Lipids; Mediterranean Countries; Oral Contraceptives; Oral Contraceptives, Combined; Physiology; Research Methodology; Research Report; Southern Europe; Studies; Thromboembolism; Thrombosis--women; Treatment; Vascular Diseases

Mesh:

Substances:

Year:  1996        PMID: 8840004     DOI: 10.1097/00001721-199606000-00011

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  5 in total

Review 1.  What is antiphospholipid syndrome?

Authors:  Doruk Erkan; Michael D Lockshin
Journal:  Curr Rheumatol Rep       Date:  2004-12       Impact factor: 4.592

2.  Possible Effect of Extended Use of Hormonal Contraception on Increased Levels of Antiphospholipid Antibodies in Infertile Women.

Authors:  Z Ulcova-Gallova; K Bibkova; Z Micanova; P Losan; K Babcova
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-03       Impact factor: 2.915

Review 3.  Which Hormones and Contraception for Women with APS? Exogenous Hormone Use in Women with APS.

Authors:  Lisa R Sammaritano
Journal:  Curr Rheumatol Rep       Date:  2021-04-30       Impact factor: 4.592

4.  The challenges of antiphospholipid syndrome: experience from diagnosis to self-care.

Authors:  Kathryn Larmour; Gareth Lewis; Gary Benson; Jennifer Hanko
Journal:  BMJ Case Rep       Date:  2014-06-26

5.  Controversies in the antiphospholipid syndrome: can we ever stop warfarin?

Authors:  Ana G Fonseca; David P D'Cruz
Journal:  J Autoimmune Dis       Date:  2008-11-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.